These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 19553790

  • 1. Combination angiostatic therapies: current status.
    Peyman GA, Fiscella R, Conway M.
    Retina; 2009 Jun; 29(6 Suppl):S18-20. PubMed ID: 19553790
    [Abstract] [Full Text] [Related]

  • 2. Rationale for combination therapy in age-related macular degeneration.
    Spaide RF.
    Retina; 2009 Jun; 29(6 Suppl):S5-7. PubMed ID: 19553803
    [Abstract] [Full Text] [Related]

  • 3. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
    Querques G.
    Am J Ophthalmol; 2009 Feb; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anti-macular degeneration agents.
    Rothen M, Jablon E, Monares G, Fontal MR, Alfaro DV.
    Ophthalmol Clin North Am; 2005 Dec; 18(4):561-7. PubMed ID: 16314219
    [Abstract] [Full Text] [Related]

  • 9. Photodynamic therapy in the anti-VEGF era.
    Fine HF.
    Br J Ophthalmol; 2007 Jun; 91(6):707-8. PubMed ID: 17510474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pathology beyond neovascularization: new targets in age-related macular degeneration.
    Heier JS.
    Retina; 2009 Jun; 29(6 Suppl):S39-41. PubMed ID: 19553799
    [Abstract] [Full Text] [Related]

  • 13. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
    Zhang SX, Ma JX.
    Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
    Hohman TC.
    Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
    Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, Blanco-Colio LM, Lorenzo O, Egido J.
    Surv Ophthalmol; 2009 Jun; 54(3):339-48. PubMed ID: 19422962
    [Abstract] [Full Text] [Related]

  • 17. Inhibiting angiogenesis in retinoblastoma.
    Apte RS, Harbour JW.
    Ophthalmic Res; 2007 Jun; 39(4):188-90. PubMed ID: 17556838
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [Abstract] [Full Text] [Related]

  • 20. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA, Rosenfeld PJ.
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.